You've decided to explore GLP-1 therapy. You've done the research. Now you're staring at two options — semaglutide or tirzepatide — and you're not sure which one to choose. They're both GLP-1 receptor agonists. They're both clinically proven. They're both available as compounded medications at a fraction of the brand-name cost.
But they're not the same. This guide gives you everything you need to make an informed decision: the mechanism, the clinical outcomes data, the side effect profiles, the cost comparison, and the specific scenarios where one drug clearly outperforms the other.
How They Work: The Mechanism
Semaglutide — GLP-1 Receptor Agonist
Semaglutide works by mimicking the GLP-1 hormone (glucagon-like peptide-1) that your gut naturally produces after eating. It binds to GLP-1 receptors in the brain's hypothalamus — the region responsible for hunger and satiety signaling — and activates the "I'm full" response. It also slows gastric emptying (food moves through your stomach more slowly) and improves glucose-dependent insulin secretion.
The result: you eat less, feel full longer, and your blood sugar is better regulated. For most patients, the reduction in appetite is significant enough that caloric intake decreases substantially without conscious effort.
Tirzepatide — GLP-1 + GIP Dual Agonist
Tirzepatide does everything semaglutide does — and adds a second mechanism. It's a dual agonist that also activates the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone, and its receptor has a different distribution pattern in the brain and in fat tissue.
The GIP pathway adds two meaningful effects:
- Enhanced insulin sensitivity in fat cells — improves the body's ability to use and store glucose efficiently
- Additive appetite suppression — the two pathways appear to work synergistically, producing a stronger combined signal than either alone
This two-pathway approach is why tirzepatide consistently outperforms semaglutide in head-to-head data.
The Clinical Outcomes: What the Data Shows
| Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Avg. body weight loss | ~15% (STEP-1, 68 weeks) | 22.5% (SURMOUNT-1, 72 weeks) Higher |
| % achieving ≥15% weight loss | ~37% | ~63% Higher |
| % achieving ≥20% weight loss | ~18% | ~40% Higher |
| Effect on HbA1c (blood sugar) | Significant reduction | Greater reduction Higher |
| Years of clinical data | ~8 years More data | ~3 years |
| FDA-approved for weight loss | Yes (Wegovy, 2021) | Yes (Zepbound, 2023) |
The STEP-1 and SURMOUNT-1 trials enrolled different patient populations and were run at different time periods, which limits direct comparison. A head-to-head trial (SURPASS-CVOT and related studies) has shown that tirzepatide produces greater weight loss than semaglutide in matched populations, but the specific numbers above come from individual trials, not a direct comparison.
Side Effects: How They Compare
Both drugs share the same class of side effects, because both act on GLP-1 receptors. The GI side effects that most patients experience early in treatment are the same for both:
- Nausea (most common, especially in the first 4–8 weeks)
- Vomiting
- Diarrhea or constipation
- Decreased appetite (therapeutic, but sometimes uncomfortable)
- Injection site reactions (mild, typically resolve quickly)
In clinical trials, tirzepatide showed a slightly higher rate of nausea compared to semaglutide — particularly in the first month. This is likely due to the additive GIP pathway mechanism and the stronger overall appetite suppression effect. For most patients, this nausea is mild, temporary, and manageable with a proper slow-titration protocol.
Both drugs carry a class warning for thyroid C-cell tumors (based on animal studies), and should not be used by patients with a personal or family history of medullary thyroid carcinoma or MEN2. Both require a provider's medical evaluation before starting.
Cost Comparison at Thinnex
Brand-name semaglutide (Wegovy) lists at over $1,300/month before insurance. Brand-name tirzepatide (Zepbound) lists at over $1,050/month before insurance. Compounded versions through Thinnex are a fraction of this cost — and critically, your price never increases as your dose escalates.
| Medication | Monthly (no commitment) | 90-Day Plan | Savings (90-day) |
|---|---|---|---|
| Semaglutide | $179/mo | $159/mo ($477 total) | $60 saved |
| Tirzepatide | $299/mo | $249/mo ($747 total) | $150 saved |
Both options include telehealth provider consultation, ongoing care team support, and free discreet shipping — no hidden fees.
Who Should Choose Semaglutide
Semaglutide is the right choice if:
Tirzepatide is the right choice if:
What About GLP-3?
If both semaglutide and tirzepatide feel like the right level of commitment but you want even stronger clinical outcomes, there's a third option worth knowing about: GLP-3 (retatrutide) — the triple agonist that adds glucagon receptor activation to GLP-1 and GIP pathways.
Phase 2 trial data showed 24.2% average body weight loss — exceeding both drugs in this comparison. It's available exclusively through providers like Thinnex as a compounded medication.
→ Read our full guide on GLP-3 (retatrutide)
Not Sure Which Is Right for You?
Our board-certified physicians review your full health history and recommend the specific medication and dose that fits your biology, goals, and medical profile. It's not a one-size-fits-all decision — and you shouldn't have to make it alone.
Get a Personalized Recommendation → Free AssessmentThe Bottom Line
Tirzepatide produces greater weight loss than semaglutide in clinical trials — on average, about 7.5 percentage points more body weight lost. For most patients with significant weight loss goals, that gap is meaningful. If maximum efficacy is the priority, tirzepatide wins.
Semaglutide is the right entry point if you're budget-conscious, GI-sensitive, or want to start with the most established protocol in the category. It has 8 years of real-world use data and a side effect profile that has been studied extensively.
At Thinnex, both are available at flat-dose pricing that never escalates as your dose increases — a key financial advantage over most GLP-1 programs. Whatever you choose, your provider will build a protocol specifically for you.
→ Also read: What Is GLP-3? The Triple Agonist Outperforming Both
→ Also read: 7 Best GLP-1 Programs in 2026 — Ranked & Compared